Dr. Kiran K Peddi

Dr. Kiran K Peddi
Gastroenterologist, Hyderabad

MBBS, MRCP,CCST

Dr. Kiran K Peddi is a consultant Gastroenterologist associated with Global Hospital and Innovate Medical Center, Hyderabad.

Specialities

  • Gastroenterology

  • Endoscopy

Procedures

  • Colonoscopy

  • Esophageal Dilatation

Expertise

  • EUS (Radial, linear and FNA)
  • ERCP
  • Double Balloon Enteroscopy
  • Colonoscopy& Polypectomies
  • EMR
  • Enteral stents
  • Variceal banding
  • Gluing of fundal varices
  • Oesophageal dilatations
  • Pyloric dilatations
  • Achalasia dilatations
  • Haemostatic techniques - Injection, Clipping, Gold probe, APC
  • PEG insertions
  • NJ tube placements

Education

  • MBBS from Kakatiya Medical College, Warangal
  • MRCP (UK), CCST(Gastro), PGDM Gastro (Salford Uni, UK), Fellowship in Interventional Endoscopy and IBD (Aus)

Practice Information

Global Hospitals, Lakdikapul

Global Hospitals, Lakdikapul

6 - 1 - 1040/1 to 4 Lakdikapul, Hyderabad, Telangana - 500004

Innovate Medical Center, Hyderabad

Innovate Medical Center, Hyderabad

3rd Floor, Ayyappa Central, 100 ft Road Ayyappa Society, Madhapur, Hyderabad, Telangana - 500081

Patient Experience

Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Kiran K Peddi and his staff know how they are doing and how they can improve their services.

Achievements & Contributions

  • 200-A multi centre double blind randomised placebo controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitis- Acting as the Principal co -investigator - writing up Protocol
  • Sub investigator for the following clinical trials
  • 2009-The Risk of skin cancer development in Inflammatory Bowel Disease Patients on Azathioprine/6-Mercaptopurine
  • 2009-Psycho-sexual function, Fertility and Sperm Integrity in Men with IBD
  • 2008-A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicentre Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis. Protocol C13006
  •  2008-A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicentre Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn's Disease. Protocol C13007
  • 2008-A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease. Protocol C13008
  • 2008-A Phase III, randomised, multi-centre, double-blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (QD) with Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis. Protocol SPD476-304
  • 2008-Study Title: A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis. Protocol number: SPD476-313
  • 2008-A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis. Protocol No. M06-827
  • 2008-A 5-Year, Registry Study of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Crohn's Disease (CD). Protocol No.: P06-134
  • 2008-A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn's disease. Protocol No.: C87085
  • 2008-A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti TNF alpha monoclonal antibody, administered at weeks 0, 2 and 4, and then every 4 weeks thereafter, in subjects with moderately to severely active Crohn's disease who have participated in study C87085. Protocol No: C87088
  • 2007-A Phase lll, Multicentre, Randomised, Placebo-Controlled, Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn's Disease (CD) Who Have Had Inadequate Clinical Response and/or Intolerance to Medical Therapy. Protocol No.IM101-084
  • 2007-A Phase lll, Multicentre, Randomised, Placebo-Controlled, Withdrawal Study to Evaluate the Clinical Efficacy and Safety of Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Colitis (UC) Who Have Had Inadequate Clinical Response and/or Intolerance to Medical Therapy. Protocol No.IM101-108
  • 2008-Protocol CDP870-034: A Phase III multi-national, multi-centre, open label, 52 week safety study to assess the safety of re-exposure after a variable interval and subsequent chronic therapy with humanised anti-TNF PEG conjugated CDP870 400mg sc, (dosed at weeks 0,2 and 4 then 4-weekly to Week 48), in the treatment of patients with active Crohn's disease who have previously been withdrawn from studies CDP870-031 or CDP870-032 due to an exacerbation of Crohn's disease
  • A randomized double blind , placebo controlled study of VSL#3 versus placebo in maintenance of remission in Crohns disease - KK Peddi et al. Journal of Gastroenterology and Hepatology 2009; 24 (suppl.2) A 317
  • Precut Sphincterotomy - is it worth the risk? - KK Peddi, DF Martin: Accepted for poster presentation at BSG 2008. Abstract no 250 in GUT March 2008,Vol57, suppl 1
  • Needle knife papillotomy in expert hands - Is it safe and effective? KK Peddi, DF Martin: Abstract in Gastrointestinal Endoscopy (GIE) - Vol 65, Number 5, April 2007 (Page AB218) and poster at DDW, Washington DC 2007
  • Experience with Endoclips in acute GI bleeds in a tertiary center: F.Mohammed, KK Peddi, C Babbs: Abstract in GUT, Poster presentation at BSG 2007
  • Muscle cramps in patients on Home parenteral Nutrition: Is there a predictable pattern? KK Peddi, F Mohammed, J Shaffer - GUT Supplement Nov Vol 55, page A180. Presented as a poster in UEGW, Berlin, October 2006
  • An interesting case of Jaundice with multisystem involvement; KK Peddi, D O'Riordan - GUT, April 2006, Supplement no.11, Vol 55, page A 32, case no.120. Electronic case presentation BSG, Birmingham, March 2006
  • The Value of 24 hr Blood Pressure Monitoring in Geriatric Population; KK Peddi, T Shawis - Journal of the American Geriatrics Society, April 2001 Number 4, 349 - 504; Abstract Number P154. Presented as a poster at American Geriatric Society annual conference, Chicago, 2001
  • TEXT BOOK CHAPTERSHow does the risk of infection influence management of IBD across the world KK Peddi, IC Lawrance - in the process of submitting to More clinical dilemmas in IBD (Blackwell publishers).
  • Submitted 4 chapters (Acute Pancreatitis, Nonvariceal Haemorrhage, Variceal Haemorrhage, Acute Dysphagia) as the first author to Gastrointestinal Emergencies section of Davidson's Acute Medicine companion (Due to come out in 2010)